CytomX Therapeutics: Doubling Overnight On Phase 1 Data

Group 1 - CytomX Therapeutics is a biotech company focused on developing novel immunotherapy approaches for various forms of cancer [1] - The company has received a bullish sentiment from analysts, indicating positive expectations for its future performance [1] Group 2 - The analyst has a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, which adds credibility to the insights provided [1] - The mission of the analyst is to educate investors on the science behind biotech businesses to help them make informed decisions [1]